1021 related articles for article (PubMed ID: 20628145)
21. Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy.
Menter T; Tzankov A
Virchows Arch; 2019 Apr; 474(4):497-509. PubMed ID: 30132131
[TBL] [Abstract][Full Text] [Related]
22. Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma.
Kim SJ; Yoon DH; Kang HJ; Hong JY; Lee HS; Oh SY; Shin HJ; Kong JH; Yi JH; Sakamoto K; Ko YH; Huh J; Lee SS; Takeuchi K; Shin DY; Suh C; Kim WS
BMC Cancer; 2019 Nov; 19(1):1080. PubMed ID: 31707975
[TBL] [Abstract][Full Text] [Related]
23. 9p24.1 Genetic Alteration and PD-L1 Expression Are Characteristic of De Novo and Methotrexate-associated Epstein-Barr Virus-positive Hodgkin Lymphoma, But Not Methotrexate-associated Hodgkin-like Lesions.
Shiraiwa S; Kikuti YY; Carreras J; Kondo Y; Ohmachi K; Ogawa Y; Kawada H; Sato S; Gion Y; Sato Y; Nakamura N; Ando K
Am J Surg Pathol; 2022 Aug; 46(8):1017-1024. PubMed ID: 35848760
[TBL] [Abstract][Full Text] [Related]
24. Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical Management.
Gupta S; Vanderbilt CM; Cotzia P; Arias-Stella JA; Chang JC; Zehir A; Benayed R; Nafa K; Razavi P; Hyman DM; Baselga J; Berger MF; Ladanyi M; Arcila ME; Ross DS
J Mol Diagn; 2019 Mar; 21(2):307-317. PubMed ID: 30576871
[TBL] [Abstract][Full Text] [Related]
25. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
[TBL] [Abstract][Full Text] [Related]
26. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma.
Traverse-Glehen A; Pittaluga S; Gaulard P; Sorbara L; Alonso MA; Raffeld M; Jaffe ES
Am J Surg Pathol; 2005 Nov; 29(11):1411-21. PubMed ID: 16224207
[TBL] [Abstract][Full Text] [Related]
27. Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification.
Chen M; Andreozzi M; Pockaj B; Barrett MT; Ocal IT; McCullough AE; Linnaus ME; Chang JM; Yearley JH; Annamalai L; Anderson KS
Mod Pathol; 2017 Nov; 30(11):1516-1526. PubMed ID: 28752839
[TBL] [Abstract][Full Text] [Related]
28. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
29. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.
Twa DD; Chan FC; Ben-Neriah S; Woolcock BW; Mottok A; Tan KL; Slack GW; Gunawardana J; Lim RS; McPherson AW; Kridel R; Telenius A; Scott DW; Savage KJ; Shah SP; Gascoyne RD; Steidl C
Blood; 2014 Mar; 123(13):2062-5. PubMed ID: 24497532
[TBL] [Abstract][Full Text] [Related]
30.
Godfrey J; Tumuluru S; Bao R; Leukam M; Venkataraman G; Phillip J; Fitzpatrick C; McElherne J; MacNabb BW; Orlowski R; Smith SM; Kline J
Blood; 2019 May; 133(21):2279-2290. PubMed ID: 30910787
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
[TBL] [Abstract][Full Text] [Related]
32. Where does PD-1 blockade fit in HL therapy?
Herrera AF
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):213-220. PubMed ID: 30504313
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review.
Sakakibara A; Kohno K; Ishikawa E; Suzuki Y; Tsuyuki Y; Shimada S; Shimada K; Satou A; Takahara T; Ohashi A; Takahashi E; Kato S; Nakamura S; Asano N
J Clin Exp Hematop; 2021 Dec; 61(4):182-191. PubMed ID: 34511582
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.
Chen BJ; Chapuy B; Ouyang J; Sun HH; Roemer MG; Xu ML; Yu H; Fletcher CD; Freeman GJ; Shipp MA; Rodig SJ
Clin Cancer Res; 2013 Jul; 19(13):3462-73. PubMed ID: 23674495
[TBL] [Abstract][Full Text] [Related]
35. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.
Balko JM; Schwarz LJ; Luo N; Estrada MV; Giltnane JM; Dávila-González D; Wang K; Sánchez V; Dean PT; Combs SE; Hicks D; Pinto JA; Landis MD; Doimi FD; Yelensky R; Miller VA; Stephens PJ; Rimm DL; Gómez H; Chang JC; Sanders ME; Cook RS; Arteaga CL
Sci Transl Med; 2016 Apr; 8(334):334ra53. PubMed ID: 27075627
[TBL] [Abstract][Full Text] [Related]
36. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain.
Shi M; Roemer MG; Chapuy B; Liao X; Sun H; Pinkus GS; Shipp MA; Freeman GJ; Rodig SJ
Am J Surg Pathol; 2014 Dec; 38(12):1715-23. PubMed ID: 25025450
[TBL] [Abstract][Full Text] [Related]
37. Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma.
Jain MD; Kuruvilla J
Drugs; 2017 Oct; 77(15):1645-1655. PubMed ID: 28819821
[TBL] [Abstract][Full Text] [Related]
38. [Microenvironment in classical Hodgkin lymphoma].
Mottok A
Pathologe; 2020 May; 41(3):254-260. PubMed ID: 32239325
[TBL] [Abstract][Full Text] [Related]
39. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
Carey CD; Gusenleitner D; Lipschitz M; Roemer MGM; Stack EC; Gjini E; Hu X; Redd R; Freeman GJ; Neuberg D; Hodi FS; Liu XS; Shipp MA; Rodig SJ
Blood; 2017 Nov; 130(22):2420-2430. PubMed ID: 28893733
[TBL] [Abstract][Full Text] [Related]
40. An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma.
Lollies A; Hartmann S; Schneider M; Bracht T; Weiß AL; Arnolds J; Klein-Hitpass L; Sitek B; Hansmann ML; Küppers R; Weniger MA
Leukemia; 2018 Jan; 32(1):92-101. PubMed ID: 28659618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
